Literature DB >> 25370486

The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases.

Gesine Respondek1, Maria Stamelou, Carolin Kurz, Leslie W Ferguson, Alexander Rajput, Wan Zheng Chiu, John C van Swieten, Claire Troakes, Safa Al Sarraj, Ellen Gelpi, Carles Gaig, Eduardo Tolosa, Wolfgang H Oertel, Armin Giese, Sigrun Roeber, Thomas Arzberger, Stefan Wagenpfeil, Günter U Höglinger.   

Abstract

The phenotypic variability of progressive supranuclear palsy (PSP) may account for its frequent misdiagnosis, in particular in early stages of the disease. However, large multicenter studies to define the frequency and natural history of PSP phenotypes are missing. In a cohort of 100 autopsy-confirmed patients we studied the phenotypic spectrum of PSP by retrospective chart review. Patients were derived from five brain banks with expertise in neurodegenerative disorders with referrals from multiple academic hospitals. The clinical characteristics of the 100 cases showed remarkable heterogeneity. Most strikingly, only 24% of cases presented as Richardson's Syndrome (RS), and more than half of the cases either showed overlapping features of several predescribed phenotypes, or features not fitting proposed classification criteria for PSP phenotypes. Classification of patients according to predominant clinical features in the first 2 years of the disease course allowed a more comprehensive description of the phenotypic spectrum. These predominance types differed significantly with regard to survival time and frequency of cognitive deficits. In summary, the phenotypic spectrum of PSP may be broader and more variable than previously described in single-center studies. Thus, too strict clinical criteria defining distinct phenotypes may not reflect this variability. A more pragmatic clinical approach using predominance types could potentially be more helpful in the early recognition of and for making prognostic predictions for these patients. Given the limitations arising from the retrospective nature of this analysis, a systematic validation in a prospective cohort study is imperative.
© 2014 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  clinical diagnostic criteria; neuropathology; phenotypes; progressive supranuclear palsy

Mesh:

Year:  2014        PMID: 25370486     DOI: 10.1002/mds.26054

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  97 in total

1.  Sensitivity and Specificity of Diagnostic Criteria for Progressive Supranuclear Palsy.

Authors:  Farwa Ali; Peter R Martin; Hugo Botha; J Eric Ahlskog; James H Bower; Joseph Y Masumoto; Demetrius Maraganore; Anhar Hassan; Scott Eggers; Bradley F Boeve; David S Knopman; Daniel Drubach; Ronald C Petersen; Erika Driver Dunkley; Jay van Gerpen; Ryan Uitti; Jennifer L Whitwell; Dennis W Dickson; Keith A Josephs
Journal:  Mov Disord       Date:  2019-02-06       Impact factor: 10.338

Review 2.  Differentiation of atypical Parkinson syndromes.

Authors:  Günter U Höglinger; Jan Kassubek; Ilona Csoti; Reinhard Ehret; Heinz Herbst; Ingmar Wellach; Jürgen Winkler; Wolfgang H Jost
Journal:  J Neural Transm (Vienna)       Date:  2017-02-27       Impact factor: 3.575

Review 3.  Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches.

Authors:  Adam L Boxer; Jin-Tai Yu; Lawrence I Golbe; Irene Litvan; Anthony E Lang; Günter U Höglinger
Journal:  Lancet Neurol       Date:  2017-06-13       Impact factor: 44.182

Review 4.  Recognizing Atypical Parkinsonisms: "Red Flags" and Therapeutic Approaches.

Authors:  Nikolaus R McFarland; Christopher W Hess
Journal:  Semin Neurol       Date:  2017-05-16       Impact factor: 3.420

5.  A Case of Apraxic Agraphia in a Patient With Progressive Supranuclear Palsy.

Authors:  Giorgia Sciacca; Tiziana Maci; Giovanni Mostile; Maria Luisa Capuana; Antonina Luca; Loredana Raciti; Cristina Sanfilippo; Francesco Le Pira; Alessandra Nicoletti; Mario Zappia
Journal:  Mov Disord Clin Pract       Date:  2015-03-30

6.  How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy.

Authors:  Max-Joseph Grimm; Gesine Respondek; Maria Stamelou; Thomas Arzberger; Leslie Ferguson; Ellen Gelpi; Armin Giese; Murray Grossman; David J Irwin; Alexander Pantelyat; Alex Rajput; Sigrun Roeber; John C van Swieten; Claire Troakes; Angelo Antonini; Kailash P Bhatia; Carlo Colosimo; Thilo van Eimeren; Jan Kassubek; Johannes Levin; Wassilios G Meissner; Christer Nilsson; Wolfgang H Oertel; Ines Piot; Werner Poewe; Gregor K Wenning; Adam Boxer; Lawrence I Golbe; Keith A Josephs; Irene Litvan; Huw R Morris; Jennifer L Whitwell; Yaroslau Compta; Jean-Christophe Corvol; Anthony E Lang; James B Rowe; Günter U Höglinger
Journal:  Mov Disord       Date:  2019-03-18       Impact factor: 10.338

Review 7.  Diagnostic Approach to Atypical Parkinsonian Syndromes.

Authors:  Nikolaus R McFarland
Journal:  Continuum (Minneap Minn)       Date:  2016-08

Review 8.  Fragile X-associated tremor/ataxia syndrome: phenotypic comparisons with other movement disorders.

Authors:  Erin E Robertson; Deborah A Hall; Andrew R McAsey; Joan A O'Keefe
Journal:  Clin Neuropsychol       Date:  2016-08       Impact factor: 3.535

9.  The role of 18F-FP-CIT PET in differentiation of progressive supranuclear palsy and frontotemporal dementia in the early stage.

Authors:  Han Soo Yoo; Seok Jong Chung; Soo-Jong Kim; Jung Su Oh; Jae Seung Kim; Byoung Seok Ye; Young Ho Sohn; Phil Hyu Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-05-04       Impact factor: 9.236

10.  Automated MRI Classification in Progressive Supranuclear Palsy: A Large International Cohort Study.

Authors:  Salvatore Nigro; Angelo Antonini; David E Vaillancourt; Klaus Seppi; Roberto Ceravolo; Antonio P Strafella; Antonio Augimeri; Andrea Quattrone; Maurizio Morelli; Luca Weis; Eleonora Fiorenzato; Roberta Biundo; Roxana G Burciu; Florian Krismer; Nikolaus R McFarland; Christoph Mueller; Elke R Gizewski; Mirco Cosottini; Eleonora Del Prete; Sonia Mazzucchi; Aldo Quattrone
Journal:  Mov Disord       Date:  2020-02-24       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.